The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | H | Systemic hormonal preparations, excl. Sex hormones and insulins | |
| 2 | H01 | Pituitary and hypothalamic hormones and analogues | |
| 3 | H01A | Anterior pituitary lobe hormones and analogues | |
| 4 | H01AX | Other anterior pituitary lobe hormones and analogues | |
| 5 | H01AX01 | Pegvisomant |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| PAREN - Parenteral | 10 mg |
| Active Ingredient | Description | |
|---|---|---|
| Pegvisomant |
Pegvisomant is an analogue of human growth hormone that has been genetically modified to be a growth hormone receptor antagonist for the treatment of adult patients with acromegaly. Pegvisomant is highly selective for the GH receptor, and does not cross-react with other cytokine receptors, including prolactin. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| SOMAVERT Powder and solvent for solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
